Sara A Hennessy on managing ICU devices in obesity (#SCCM2023)
BP cuffs taken with too-small cuffs significantly higher. Should be 80% of upper arm circumference, width should be 40% of length. Large cuffs may still be poor fit, eg too long (obese arms aren't longer), and arms are "inverted cones" not cylinders.
Try an appropriate cuff on forearm, hold forearm at level of heart; hoses should exit over radial artery. Will vary by 7-15mmHg from upper arm.
Abdominal pressure in obesity: IAP may be elevated a little in obesity, but not by much (<1mmHg). IAH numbers in obesity is still IAH.
IV placement in obesity: try warming; displace edema/tissue; use multiple tourniquets; use a longer line; try translumination; avoid small collateral vessels. Mostly, use ultrasound.
CVC placement: more anatomic variation in neck; use ultrasound! may need to use an extended-access needle to reach vessel for wire placement. (Note: higher risk of damaging intrathoracic structures with long needle.)
Remember line can shift with tissue movement/repositioning and extravasate. Consider how much catheter is intravascular, and frequently check position; may need imaging.
BMI >40 = double risk of CLABSI
Placing doubled sono-opaque markers on US probe dramatically increases arterial cannulation success in obesity
Keyser: cannulation for VV ECMO technically harder but can have good outcomes and success.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Allan Walkey on atrial fibrillation in ICU (#SCCM2023)
Arrigo 2015: cardioversion for secondary A-fib in ICU rarely works (43% remains sinus at 1hr, 23% at 24hr). Diltiazem was more effective at rate control than amio or digoxin.
Walkey 2016: Afib in sepsis? Association on outcome of BB vs CCB, BB vs digoxin, BB vs amiodarone compared. BB had slightly lower mortality than CCB.
Bosch 2021: BB achieved more HR reduction than amiodarone, CCB, and dioxin at 1hr (CCB was highest at 6 hours).
Davey 2005: magnesium was about as effective at rhythm control as amiodarone.
Remember untreated infection, volume status, presence of beta agonists.
Law 2022: phenylephrine vs norepinephrine for shock? HR difference was only about 2-6 only, even in the subgroup with RVR.
Kevin Betthauser on empiric anaerobic antibiotics in the ICU (#SCCM2023)
gut dysbiosis common in ICU patients. Gut integrity degrades. Reduction in firmicutes and bacteriodetes, increase in proteobacteria. Less commensals, more opportunistic infections.
In animal models, depletion of anaerobes increases susceptibility to bacterial PNA, lung injury, mortality. Preserving anaerobes by SDD associated with less VAP, less mortality. (Szychowiak 2022, Hammond 2022)
ATS/IDSA 2019 CAP guidelines: suggest not routinely covering aspiration pneumonia for anaerobes. Modern syndromes typically CAP organisms, not anaerobic. Kioka 2017, Marrin-Corral 2021, Brummitt 2022 - show anaerobic coverage is downtrending over past five years.
clear standard of care for bronchoconstriction, but mostly used for hypoxemic disease because it "can't hurt". Ehrmann 2013 European survey found 95% used them routinely in mechanically ventilated
BALTI trial: IV B-agonists for ALI improved resolution of alveolar edema and survival
Perkins 2014: salmeterol didn't improve ALI
BALTI-2: salbutamol, stopped for harm
Routine nebs create significant workload and disposable equipment burden
Device types vary by efficiency, but we use so much drug it likely doesn't matter - it gets delivered.
Shelby Yaceczko on nutrition in critical illness + obesity (#SCCM2023)
malnourished inpatients have 3.4x risk of in-hospital death, but only 2.7% of patients with coded malnutrition actually receive enteral nutrition in the hospital.
malnutrition in ICU associated with length of stay, higher cost of care. ASPEN did a value analysis, shows nutrition support saves money (projected $222 million yearly Medicare savings).
ASPEN 2021 guidelines:
1. How much should you give? No difference between high and low levels of nutrition. Give 12-25 kcal/kg BW in first 7-10 days of ICU stay. (Old recs: depended on disease and malnutrition risk.)
Bethany Shoulders on Pharmacotherapy in critical illness + obesity (#SCCM2023)
Absorption: may be reduced both enteral and subq
Distribution: Increased
Metabolism: may decrease
Excretion: Often increased
B-lactams (inc. cephalosporins, meropenem, pip/tazo): good data on impact of obesity. more treatment failure, longer hospitalizations, risk of cefepime neurotoxicity. Use monitoring! Target 40-100% free time >MIC.
Anticoagulation (enoxaparin, heparin): Use higher dose for prophylaxis. No dose cap for weight-based dose of enoxaparin. May not need heparin dose increase unless BMI >50. For therapeutic heparin, slight preference to adjusted BW + no cap.